why choose us

First received: March 03, 2023

Clinical Trial: A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Brief Summary: The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients.The main questions the study aims to answer are:can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients.will JNJ-90009530 help patients achieve a response and for how long?

Read more